St. Jude Children's Research Hospital Aug 13 2025 A computational approach by St. Jude Children's Research Hospital scientists promises to make designing T cell-based immunotherapies that target two cancer-related antigens at the same time far easier and faster. Chimeric antigen receptor (CAR) T cells are a type of immunotherapy that reprograms a patient's immune cells to target a tumor-specific protein antigen. Targeting just one cell surface antigen often is not enough to eradicate the tumor.